Talimogenlaherparepvec
Produte Talimogenlaherparepvec is commercially available as a suspension for injection (Imlygic). It was approved in the United States in 2015 and in the EU and Switzerland in 2016. Structure and properties Talimogenlaherparepvec is attenuated herpes simplex virus 1 (HSV-1) virus that has been genetically engineered to produce human granulocyte macrophage colony stimulating factor (GM-CSF). GM-CSF … Talimogenlaherparepvec